01Role and principlesWho benefits and the main preventive aims.
A screening programme is justified only when the condition is important, the target population and test are defined, the pathway from result to treatment is available, benefits outweigh harms and quality can be audited. Screening can shift diagnosis earlier, but apparent survival gains may reflect lead-time bias, preferential detection of slower disease or overdiagnosis. Mortality and serious morbidity, rather than five-year survival alone, are therefore important outcome measures.
Each programme is a pathway rather than a single test. Invitation and information are followed by the initial screen, laboratory or imaging quality assurance, recall of abnormal results, diagnostic colposcopy, colonoscopy or breast assessment as appropriate, pathology, treatment and failsafe tracking. A positive result changes probability; tissue or definitive specialist assessment establishes diagnosis. A negative result lowers but never abolishes probability.
Primary care should help people understand invitations, identify reasonable adjustments and act on results that have not reached the intended service. Clinicians must keep symptomatic care separate. Postmenopausal bleeding, a new breast mass, persistent rectal bleeding or another concerning change requires assessment under symptomatic guidance even if the last screen was normal.
Key points
- Screening offers a test to an apparently well defined population to reduce disease-specific harm; it is not a guarantee that cancer is absent.
- UK population programmes include bowel, breast and cervical screening. In England, targeted lung cancer screening is rolling out for people aged 55–74 with a smoking history: risk assessment determines who is offered low-dose CT, and current availability and criteria must be checked locally and by UK nation.
- The first-line test is programme-specific: for example faecal immunochemical testing in bowel screening and primary HPV testing in cervical screening pathways.
- An abnormal screen requires the programme's diagnostic assessment; it is not itself a cancer diagnosis and many recalled people will not have malignancy.
- Symptoms use a symptomatic pathway regardless of age or recent screening result, because screening sensitivity is incomplete and interval cancers occur.
- Informed choice includes benefits, false positives, false negatives, overdiagnosis, anxiety and procedural harm, presented accessibly without coercion.
- Non-response can reflect language, disability, trauma, deprivation or access barriers; services should offer reasonable adjustment rather than labelling disengagement.
- Incidental or private tests outside an evaluated programme may create uncertain findings and should not be treated as equivalent to national screening.
02Assessment and patient selectionRisk features, eligibility and important cautions.
The programme defines age, sex or organ-based eligibility and interval; current national criteria should be checked rather than recalled from memory.
A positive HPV, faecal test or recalled mammogram increases risk and triggers a programme-defined diagnostic step, not immediate cancer labelling.
A returned test without a recorded result, non-attendance after recall or failed sample requires active failsafe follow-up.
New bleeding, lump, unexplained weight loss or persistent change requires diagnostic assessment even after a recent negative screen.
Learning disability, language need, physical limitation, gender dysphoria, previous trauma or deprivation may require tailored information and practical support.
03Baseline assessmentMeasurements that guide the plan and track progress.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Programme eligibility checkFirst step - Why
- Confirm whether the person belongs to the current invited cohort.
- Interpretation and limitations
- Use the applicable UK nation's live programme criteria, previous results and relevant organ status; do not infer eligibility from gender marker alone.
- 02
Initial screening test - Why
- Estimate risk in an asymptomatic invited population.
- Interpretation and limitations
- Use only the programme test and threshold: examples include FIT, primary HPV testing, mammography, or formal lung-risk assessment followed by low-dose CT when the targeted lung programme indicates it. A positive screen is not diagnostic histology.
- 03
Programme diagnostic assessment - Why
- Resolve an abnormal screen using the designated specialist test.
- Interpretation and limitations
- Colonoscopy, colposcopy or triple breast assessment is selected by programme and result; findings determine biopsy, surveillance or return to routine recall.
- 04
Histopathology - Why
- Confirm and classify a screen-detected precursor or cancer.
- Interpretation and limitations
- Use RCPath reporting and multidisciplinary review; inadequate or discordant tissue may require repeat sampling rather than reassuring assumption.
- 05
Symptom-led assessment - Why
- Investigate possible cancer outside screening when clinical features are present.
- Interpretation and limitations
- Follow NG12 or acute pathways according to feature severity; a prior negative screen modifies probability but does not close referral.
04InterventionsLifestyle, treatment and escalation options.
01InviteSupport informed participationFirst stepAn eligible person receives or has missed a screening invitation.+
- 1PreferredExplain the programme's purpose, likely next steps, main benefits and harms in the person's preferred accessible format.
- 2Check practical barriers and arrange translated material, accessible venue, bowel-test support or other reasonable adjustment through the programme.
- 3Respect an informed decision to accept or decline, while documenting how to seek advice if symptoms develop.
02RecallComplete abnormal-result assessmentThe initial screen is abnormal, inadequate or repeatedly unreturned.+
- 1Confirm that the person received the result and understands that it requires assessment but does not yet establish cancer.
- 2Use the programme's required diagnostic service and timescale, checking medicines, comorbidity and procedural support needs.
- 3Track attendance, pathology and final disposition through failsafe systems so the episode cannot disappear between organisations.
03SymptomsLeave the screening pathwayPossible-cancer symptoms appear before, during or after routine screening.+
- 1Assess acuity, examination and the appropriate NG12 symptom criteria without repeating a screening test as a diagnostic substitute.
- 2Refer to the site-specific diagnostic pathway or emergency service and provide safety-net timing for progression or non-resolution.
- 3Tell the screening programme when relevant, but do not wait for its next invitation or routine recall decision.
05Targets, monitoring and follow-upResponse, safety and longer-term review.
- Confirm completion of each abnormal-result episode, including diagnostic test, pathology, multidisciplinary decision and communication to the person and primary care.
- Use programme failsafe reports to identify missing samples, unreported tests, unattended recalls and delayed pathology before harm occurs.
- Audit uptake by deprivation, ethnicity, disability and other access factors, then redesign outreach where inequalities persist.
- Record informed decline without removing future invitation rights, and make clear how to re-enter the programme where policy allows.
- Continue ordinary symptom surveillance and health care between rounds; screening intervals are not symptom-review intervals.
06Special situationsVariants, exceptions and circumstances that change the usual approach.
Positive is not diagnosis
The positive predictive value depends on prevalence and programme threshold, so most abnormal screens require a separate diagnostic test.
Negative is not exclusion
Sensitivity is incomplete and disease can arise between rounds; persistent clinical features still need a diagnostic pathway.
Overdiagnosis is real
Some detected cancers would not have caused harm within the person's lifetime, but an individual result rarely reveals which lesion that is.
Survival can mislead
Earlier detection automatically lengthens measured survival from diagnosis even when death is unchanged; mortality outcomes better address lead-time bias.
Failsafe is clinical care
Tracking a positive result to final disposition is as important as performing the initial test accurately.
07Common pitfallsFrequent interpretation and management errors.
- 01
Using screening tests to investigate symptoms.
- 02
Calling an abnormal screen cancer before diagnosis.
- 03
Quoting outdated eligibility from memory.
- 04
Ignoring a missing or inadequate result.
- 05
Coercing participation rather than supporting informed choice.
- 06
Assuming non-attendance reflects indifference in clinical practice.
- 07
Forgetting interval cancers after a negative screen.